Prostate

TITRE (EN) Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer
PROTOCOLE ID ANCHOR-Prostate
CLINICAL TRIAL.gov ID NCT05457699
TYPE(S) DE CANCER Prostate
PHASE Phase II
TYPE D'ÉTUDE Clinique
INSTITUTION CHUM
1051 rue Sanguinet
(514) 890-8000
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Cynthia Ménard
COORDONATEUR(RICE) Mom Phat
mom.phat.chum@ssss.gouv.qc.ca
514-890-8000 poste 11171
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Enrolled in PERa (CHUM CER 17.032) and randomly selected for AnChoR-Prostate.
  • Diagnosis of metastatic prostate cancer having achieved maximum PSA response to SOC systemic therapy defined as two consecutive stable PSA within 6 months of regimen start. Stable PSA is defined as non- progressing (<25% rise from nadir, per PCWG3 guidelines).
  • ECOG 0-2
  • PSA > 0.2 ng/mL
  • 1-5 sites of PSMA-PET avid disease amenable to SABR.
CRITÈRES D'EXCLUSION (EN)
  • none